Washington: Researchers have found that people, who have an advanced form of lung cancer that carries a specific dysfunctional gene, are likely to fare better if they are treated with a targeted therapy than with traditional chemotherapy.In a trial involving patients with non-small cell lung cancer (NSCLC) whose tumour cells harboured an abnormal ALK gene, those who received the oral drug crizotinib, which acts directly on ALK, went a median time of 7.7 months before their disease began to worsen, compared to 3 months for patients who received traditional chemotherapy.
Pak asks for DGMO meet with India to address border firing
Communal violence on rise in BJP rule: Mayawati
CCTV captures chain snatcher at Wadala station
SC refuses to postpone UPSC preliminary examination